Clinical trial
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With…
NCT00482014 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00482014 |
|---|---|
| Title | A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer |
| Official title | Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Cancer (NSCLC) |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | pemetrexed, cisplatin, carboplatin, radiation therapy |
| Enrollment | 120 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jun 4, 2007 |
| Last update posted | Nov 27, 2012 |
| Countries | India, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: